Narayana Hrudayalaya Ltd.
| BSE: 539551 | Sector: Health care |
| NSE: NH | ISIN Code: INE410P01011 |
| BSE 00:00 | 23 May | 633.10 |
-30.35 (-4.57%) |
OPEN
675.00 |
HIGH
675.00 |
LOW
630.45 |
| NSE 00:00 | 23 May | 633.60 |
(%) |
OPEN
675.00 |
HIGH
680.00 |
LOW
630.00 |
| OPEN | 675.00 |
| PREVIOUS CLOSE | 663.45 |
| VOLUME | 12240 |
| 52-Week high | 775.00 |
| 52-Week low | 425.95 |
| P/E | 96.80 |
| Mkt Cap.(Rs cr) | 12,938 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Narayana Hrudayalaya Ltd. (NH) - News Sector
-
Amazon, Flipkart in talks to buy stake in $1 bn diagnostic chain Metropolis
12.45 am | 21 May 2022 | Bloomberg
Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
-
Board evaluating Sebi penalty of Rs 1 crore, says Fortis Healthcare
11.33 pm | 20 May 2022 | Business Standard
Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
-
Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%
11.31 pm | 20 May 2022 | Business Standard
Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures
-
Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%
2.33 pm | 20 May 2022 | Business Standard
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
-
Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit
1.08 am | 20 May 2022 | Business Standard
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
-
Dr Reddy's plans new brands in Russia, says no issue with funds in country
12.55 am | 20 May 2022 | Business Standard
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
-
Lupin slips 9%, hits 2-year low on disappointing March quarter results
9.39 am | 19 May 2022 | Business Standard
Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
-
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit
9.35 pm | 18 May 2022 | Business Standard
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
-
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD
9.25 pm | 18 May 2022 | Business Standard
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
-
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra
9.22 pm | 18 May 2022 | Business Standard
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
-
Rejuvenating Cipla: After global expansion, acquisitions on cards
9.18 pm | 18 May 2022 | Business Standard
Having consolidated its presence across geographies, the pharma major is looking at acquisitions
-
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts
3.16 pm | 18 May 2022 | Business Standard
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
-
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results
9.52 am | 18 May 2022 | Business Standard
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
-
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%
1.47 am | 18 May 2022 | Business Standard
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
-
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations
12.42 pm | 17 May 2022 | Business Standard
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
-
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore
1.05 am | 17 May 2022 | Press Trust of India
Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
-
USFDA rush after 2-year lull: 20-30% new products may be open to inspection
3.01 am | 16 May 2022 | Business Standard
The last two years saw limited physical inspections due to travel restrictions during the pandemic
-
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol
12.04 am | 14 May 2022 | Business Standard
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
-
Cipla looks to invest more in mRNA tech; holds discussions with firms
2.03 am | 12 May 2022 | Business Standard
Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
-
Cipla will use Covid-19 bulk drugs inventory when demand rises
11.46 pm | 11 May 2022 | Business Standard
The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
Quick Links for Narayana Hrudayalaya:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
